FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Marrone Pamela G 2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2013 3. Issuer Name and Ticker or Trading Symbol MARRONE BIO INNOVATIONS INC [MBII] (Last) (First) (Middle) C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, SUITE A-107 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO and President 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) DAVIS, CA 95618 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 712,375 D   Common Stock 47,898 I Jointly with Spouse Common Stock 5,753 I By Trust (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	  (2)	05/01/2017	Common Stock	53,378	$ 0.47	D	Â
Stock Option (Right to Buy)	  (3)	10/22/2018	Common Stock	47,794	$ 1.19	D	Â
Stock Option (Right to Buy)	  (4)	01/28/2019	Common Stock	9,559	$ 1.19	D	Â
Stock Option (Right to Buy)	  (5)	01/11/2020	Common Stock	4,779	$ 1.19	D	Â
Stock Option (Right to Buy)	  (6)	01/24/2021	Common Stock	19,092	$ 1.19	D	Â
Stock Option (Right to Buy)	  (7)	01/24/2021	Common Stock	31,863	$ 1.19	D	Â
Stock Option (Right to Buy)	  (8)	12/15/2021	Common Stock	31,863	$ 1.41	D	Â
Stock Option (Right to Buy)	  (9)	02/20/2022	Common Stock	15,390	$ 3.11	D	Â
Stock Option (Right to Buy)	  (10)	10/18/2022	Common Stock	63,726	$ 12.08	D	Â
Convertible Promissory Note	  (11)	  (11)	Common Stock	$ 25,000 (11)	$ (11)	I	Jointly with Spouse
Convertible Promissory Note	  (11)	  (11)	Common Stock	$ 5,049 (11)	$ (11)	I	By Trust (1)
Convertible Promissory Note	  (12)	  (12)	Common Stock	$ 15,000 (12)	$ (12)	I	Jointly with Spouse

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Marrone Pamela G C/O MARRONE BIO INNOVATIONS, INC. 2121 SECOND STREET, SUITE A-107 DAVIS, CA 95618	  X	Â	  CEO and President	Â

Signatures

/s/ Donald J. Glidewell, Donald J. Glidewell, Attorney-in-Fact		08/01/2013
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Ownership is held by Florence H. Marrone TOD Pamela G. Marrone.
(2)	The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of May 1, 2007, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
(3)	The option vested with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of November 1, 2008, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
(4)	The option vests with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2009, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
(5)	The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2010.
(6)	The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011.
(7)	The options vest with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2011, and 1/48th of the total shares subject to the options monthly thereafter for 36 months.
(8)	The options vest with respect to 1/60th of the total shares subject to the option one month after the vesting commencement date of November 1, 2011, and 1/60th of the total shares subject to the option monthly thereafter for 36 months.
(9)	The options vested with respect to 100% of the total shares subject to the option on the vesting commencement date of February 20, 2012.
(10)	The option vests with respect to 1/4th of the total shares subject to the option on October 18, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months.
(11)	Lists original principal under the convertible promissory note as of March 16, 2012, the date of purchase. Upon completion of the Issuer's initial public offering, such principal, plus all accrued interest, will automatically convert into common stock at a price per share equal to 70% of the price per share in the Issuer's initial public offering.
(12)	Lists original principal under the convertible promissory note as of May 28, 2013, the date of purchase. Upon completion of the Issuer's initial public offering, such principal, plus all accrued interest, will automatically convert into common stock at a price per share equal to 70% of the price per share in the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.